Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Novavax, Inc.NASDAQ: NVAX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $95.47M rose 7.3% year over year, ahead of the -10.9% change in trailing-twelve-month research & development. Sequentially, it rose 29.1% from the prior quarter. Over 3 fiscal years it compounded at -35.2% a year.

Context

  • Research & development amounted to 30.0% of revenue in FY2025, down 27.4 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.3% holds above the trailing-twelve-month pace of -10.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$95.47M+29.1% QoQ
Last fiscal yearDec 2025
$336.82M-13.9% YoY
LTMMar 2026
$345.36M-10.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.3%——
1 year-13.9%——
3-year CAGR-35.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
336.82M USD
Year-over-year change
-13.9%
4-year CAGR
-39.6%

Research & Development vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.9% is the 4th highest of 8, against a peer median of -23.6%.
  • Research & development amounts to 57.9% of revenue for NVAX, versus a peer median of 82.6%.
NVAX Competitors
Research & Development for NVAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$2.66B USD-23.6%-1.7%105.3%
BNTXBioNTech SELTM Jun 2026€2.18B EUR-0.6%+9.6%82.6%
PCVXVaxcyte, Inc.LTM Jun 2026$1.03B USD+74.2%+67.4%—
NVAXNovavax, Inc.LTM Mar 2026$345.36M USD-10.9%-35.2%57.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M USD-44.3%-8.8%216.6%
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$51.51M USD-27.2%-33.9%—
EBSEmergent BioSolutions Inc.LTM Mar 2026$49.1M USD-30.6%-34.1%7.3%
Peer median (excluding NVAX) —-23.6%-6.7%82.6%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue197.58M1.6B556.38M682.16M1.12B
Cost of Revenue0902.64M343.77M202.74M71.14M
Gross Profit197.58M696.31M212.61M479.42M1.05B
Gross Margin100.0%43.5%38.2%70.3%93.7%
Research & Development2.53B1.24B737.5M391.17M336.82M
Selling, General & Admin298.36M488.69M468.95M337.19M150.35M
Operating Expenses1.88B1.34B779.13M728.35M489.07M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
EBITDA(1.68B)(604.71M)(487.39M)(108.04M)492.33M
EBITDA Margin-850.7%-37.8%-87.6%-15.8%43.8%
Operating Income(1.69B)(644.74M)(566.51M)(248.93M)563.27M
Operating Margin-853.6%-40.3%-101.8%-36.5%50.1%
Interest Income00000
Interest Expense21.13M19.88M14.42M20.08M22.55M
Other Income / Expenses(27.96M)(8.91M)23.48M72.32M(121.1M)
Income Before Tax(1.71B)(653.65M)(543.03M)(176.62M)442.17M
Pre-Tax Margin-867.8%-40.9%-97.6%-25.9%39.4%
Income Tax Expense29.22M4.29M2.03M10.88M1.87M
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Net Margin-882.5%-41.1%-98.0%-27.5%39.2%
EPS (Basic)(23.44)(8.42)(5.41)(1.23)2.72
EPS (Diluted)(23.44)(8.42)(5.41)(1.23)2.54
Weighted Avg Shares74.4M78.18M100.77M152.19M161.99M
Weighted Avg Shares (Diluted)74.4M78.18M100.77M152.19M173.1M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.